GlobeNewswire

ProMIS Neurosciences to develop multivalent vaccine for Alzheimer’s disease

Share

Potential vaccine to incorporate ProMIS proprietary peptide antigens; early in vivo preclinical data demonstrate neuronal protection and improvement in cognitive deficits

TORONTO and CAMBRIDGE, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today initiation of a program to construct and test a multivalent peptide vaccine for Alzheimer’s disease (AD). The critical first steps in vaccine development will be carried out by VIDO-InterVac, a global leader in vaccine research and development.

Recent progress in the development of blood-based biomarkers for neurodegeneration is enabling increased screening to diagnose and identify individuals at risk of developing AD. A vaccine capable of inducing an effective antibody response against amyloid-beta toxic oligomers (ABOs) could be administered prophylactically to at-risk individuals to prevent development of symptomatic disease. Additionally, the vaccine could be given therapeutically to individuals living with a diagnosis of AD to inhibit further disease progression.

In a proof-of-concept study, ProMIS identified six different peptide epitopes selectively exposed on toxic ABOs. Immunization of mice with each of these individual epitopes produced protective antibodies against ABOs, without undesirable binding to amyloid-beta monomers or fibrils. ProMIS also conducted a successful proof-of-concept vaccination study with one of the peptide epitopes in a mouse model of AD, which demonstrated neuronal protection and improvement in cognitive deficits.1

“Again demonstrating the versatility of ProMIS’ proprietary discovery platform, we’re now advancing our program to develop a safe and effective vaccine to induce a specific immune response against toxic ABOs, a root cause of AD,” stated Dr. Neil Cashman, ProMIS’ Chief Scientific Officer. “The encouraging initial results clearly support the development of a multivalent vaccine for AD prevention, uniquely positioning ProMIS as offering a three-pronged approach to combat AD: detect with blood-based biomarkers, treat with PMN310, and prevent with a vaccine.”

Vaccine development will start at the University of Saskatchewan’s Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac) with the generation of multivalent vaccine constructs based on the ProMIS peptides linked to a carrier protein and formulated with an adjuvant to maximize induction of a protective antibody response to ABOs.

About VIDO-InterVac
The University of Saskatchewan’s VIDO-InterVac is internationally recognized for its role in vaccine development and is one of Canada’s national science facilities. VIDO-InterVac has a 45-year history of vaccine development and commercialization – eight of its vaccines have been sold commercially, and six have been described as world-firsts. The ~150-member organization operates using an ISO:9001 certified management system in state-of-the-art containment level 2 and 3 facilities. VIDO-InterVac receives operational support from the Canada Foundation for Innovation’s Major Science Initiatives Fund and the Government of Saskatchewan through Innovation Saskatchewan and the Agriculture Development Fund.

Visit us at www.vido.org or follow us on Twitter and LinkedIn.

Corporate Update
We announce today the resignation of Anthony Giovinazzo from the Board of Directors of ProMIS Neurosciences. We thank Anthony for his significant contributions to the company since he joined the Board of Directors over 3 years ago and wish him much success in his future endeavors.

About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company whose unique core technology is the ability to rationally predict the site and shape (conformation) of novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of proteins. In neurodegenerative diseases, such as Alzheimer’s, ALS and Parkinson’s disease, the DSEs are misfolded regions on toxic forms of otherwise normal proteins. In the infectious disease setting, these DSEs represent peptide antigens that can be used as an essential component to create accurate and sensitive serological assays to detect the presence of antibodies that arise in response to a specific infection, such as COVID-19. ProMIS proprietary peptide antigens can also be used to create potential therapeutic antibodies, as well as serve as the basis for development of vaccines. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

Visit us at www.promisneurosciences.com or follow us on Twitter and LinkedIn. To learn more about diagnostic testing for Alzheimer’s disease, listen to Episode 26 of the podcast, Saving Minds, available at iTunes or on ProMIS Neurosciences’ website.

References:

1Silverman J et al. “A rational structured epitope defines a distinct subclass of toxic amyloid-beta oligomers” (2018), ACS Chem Neurosci; 9: 1591-1606.

For media inquiries, please contact:
Shanti Skiffington
shanti.skiffington@gmail.com
Tel. 617 921-0808

For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
nick@alpineequityadv.com
Tel. 617 901-0785

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Key dates for the Yara International ASA 2019 dividend23.10.2020 17:33:48 CESTPress release

Oslo, 23 October 2020: Reference is made to Yara’s stock exchange release dated 23 October 2020 regarding the Extraordinary General Meeting and additional dividend of NOK 18 per share. The following key dates will apply for the additional dividend: Ex dividend NOK 18.00 as of: 18 November 2020 Record date: 19 November 2020 Dividend payment date: 27 November 2020 ADR dividend payment date: 4 December 2020 Contact Thor Giæver, Investor Relations Cellular: (+47) 480 75 356 E-mail: thor.giaver@yara.com About Yara Yara grows knowledge to responsibly feed the world and protect the planet. Supporting our vision of a world without hunger, we pursue a strategy of sustainable value growth, promoting climate-friendly and high-yielding crop nutrition solutions for the world’s farming community and food industry. Yara’s ambition is to be the Crop Nutrition Company for the Future. We are committed to creating value for our customers, shareholders and society at large, as we work to develop a more su

Nøkkeldatoer for Yara International ASA tilleggsutbytte23.10.2020 17:33:48 CESTPressemelding

Oslo, 23. oktober 2020: Det vises til børsmelding 23. oktober 2020 om ekstraordinær generalforsamling og tilleggsutbytte på 18 kroner per aksje. Følgende nøkkeldatoer gjelder for tilleggsutbyttet: Aksjen handles eks. utbytte NOK 18,- fra: 18. november 2020 Eierregisterdato: 19. november 2020 Utbetalingsdato: 27. november 2020 Utbetalingsdato ADR: 4. desember 2020 Kontakt Thor Giæver, investorkontakt Mobil: (+47) 480 75 356 E-post: thor.giaver@yara.com Om Yara Yara bringer kunnskap om hvordan verdens befolkning kan mettes og kloden beskyttes. Bak vår visjon om en verden uten sult ligger en strategi som fremmer klimavennlige og ressurseffektive løsninger for landbruk og matvareindustri over hele verden. Vår ambisjon er å være fremtidens leverandør av plantenæring. Vi har forpliktet oss til å skape verdi for kunder, aksjonærer, og samfunnet rundt oss i arbeidet med å skape en mer bærekraftig matverdikjede. For å nå dette målet, har vi satt oss i førersetet for utviklingen av digitale verk

Kommuniké från extra bolagsstämma den 23 oktober 2020 i Saniona AB23.10.2020 17:15:00 CESTPressemelding

PRESSMEDDELANDE 23 oktober 2020 Idag, den 23 oktober 2020, hölls extra bolagsstämma i Saniona AB. Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med erforderlig majoritet. Beslut om (A) personaloptionsprogram; och (B) riktad emission av teckningsoptioner samt godkännande av överlåtelse av teckningsoptioner Stämman beslutade, i enlighet med styrelsens förslag, om införande av ett optionsprogram för samtliga av bolagets anställda, inklusive bolagets verkställande direktör, ledningsgrupp (exklusive CSO Jørgen Drejer), Vice Presidents och samtliga övriga anställda. Personaloptionerna omfattar samtliga av bolagets nuvarande anställda (inklusive nyligen anställda och personer som kommer att anställas under perioden fram till nästa årsstämma). Stämman beslutade även om riktad emission av teckningsoptioner samt godkännande av överlåtelse av teckningsoptioner. Programmet innebär att högst 7 976 690 personaloptioner ska erbjudas deltagarna. Optionsinnehavarna

Bulletin from the extraordinary general meeting on October 23, 2020 in Saniona AB23.10.2020 17:15:00 CESTPress release

PRESS RELEASE October 23, 2020 The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. Today, on October 23, 2020, an extraordinary general meeting was held in Saniona AB. A summary of the resolutions adopted follows below. All resolutions were adopted with the required majority of votes. Resolution on (A) employee option program; and (B) directed issue of warrants and approval of transfer of warrants The meeting resolved, in accordance with the proposal from the board of directors, to adopt an option program for all company employees, including the company’s CEO, the executive team (excluding the CSO Jørgen Drejer), vice presidents and all other employees. The employee options will cover all current employees, including the employees that have recently been hired, as well as the employees that will be hired up until the next annual general meeting (AGM). The meeting also resolved

PRF: Subsidiary of AS PRFoods is borrowing from the Rural Development Foundation23.10.2020 17:00:00 CESTPress release

AS PRFoods has approved the borrowing of the six-year investment loan in the amount of one million euros from the Rural Development Foundation by its subsidiary Osaühing Vettel under the measure „COVID-19 loan to bio- and rural enterprises” (aid measure 3.3). The interest rate of the loan will be 2.5% for the first two years and 4.5% thereafter. The investment loan shall be used for automatization of the factory of Osaühing Vettel in Saaremaa. The loan is secured by a mortage and a commercial pledge on the assets of Osaühing Vettel to the following rankings of existing creditors and a 100% guarantee from AS PRFoods. Indrek Kasela AS PRFoods Mermber of the Management Board T: +372 452 1470 investor@prfoods.ee www.prfoods.ee

Notice of Yara Extraordinary General Meeting23.10.2020 16:30:00 CESTPress release

Oslo, 23 October 2020: Yara International ASA will hold an Extraordinary General Meeting on Tuesday 17 November at 17:00 CET to approve the Board’s proposal to pay an additional dividend of NOK 18 per share. The meeting notice is available on the company’s website. In accordance with Norwegian temporary legislation exempting companies from physical meeting requirements to reduce Covid-19 risk, the Extraordinary General Meeting will be held as a digital meeting only, with no physical attendance for shareholders. The complete notice of the Annual General Meeting will be distributed to Yara’s registered shareholders and is also available on Yara’s website: https://www.yara.com/investor-relations/reports-and-presentations-2020/ Contact Thor Giæver, Investor Relations Cellular: (+47) 480 75 356 E-mail: thor.giaver@yara.com About Yara Yara grows knowledge to responsibly feed the world and protect the planet. Supporting our vision of a world without hunger, we pursue a strategy of sustainable